Trials / Completed
CompletedNCT07023016
Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure - CAESAR (a Randomized Controlled Trial)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 515 (actual)
- Sponsor
- National Heart Institute, Egypt · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Sacubitril/valsartan is an established medication for heart failure. However, data still lags in its use in heart failure patients with chronic kidney disease. Sacubitril/valsartan is manufacturer-labeled for use in patients with eGFR \< 30 ml/min/1.73 m2 at an initial dose of 24/26mg twice daily. However, to the best of our knowledge, the concept of sacubitril/valsartan or ACEi in patients with chronic kidney disease \& presenting with decompensated heart failure has not yet been explored fully.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacubitril / Valsartan | Patients will receive sacubitril/valsartan at an initial dose of 24/26 mg Bid. |
| DRUG | Ramipril (ACE-inhibitor) | Patients will receive ramipril at an initial dose of 2.5 mg Bid. |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2025-02-28
- Completion
- 2025-02-28
- First posted
- 2025-06-15
- Last updated
- 2025-06-22
Locations
2 sites across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07023016. Inclusion in this directory is not an endorsement.